Chemotherapy is one of the common treatments for cancer patients. Many types of chemotherapy have already been utilized for cancer patients and a number of novel chemotherapy drugs have been developed and evaluated under clinical trials. Importantly, some chemotherapy targets only cancer cells that harbor a specific mutation that drives cancer development. Therefore, targeted chemotherapy could reduce side effects and burden for cancer patients. However, tumors relapse due to resistance after prolonged chemotherapy. In order to improve treatment outcomes and suppress drug resistance for cancer patients, understanding the resistance mechanisms to chemotherapy is of clinical necessity.
While drug resistance is associated with a number of factors such as amplification/activation of oncogenes, loss/inactivation of tumor suppressor genes, dysregulation of transcriptional networks, altered metabolism and microenvironment, little is known about the resistance mechanisms to chemotherapy by alteration of epigenetic modifiers.
This Research Topic focuses on epigenetic modification related transcriptional networks in the context of drug resistance. We welcome basic science that focuses on identification of novel epigenetic modifiers that can be targeted for treatment and translational science that assesses the efficacy of drug combinations with drugs targeting epigenetic modifiers in cancer.
We encourage submissions of original research as well as review articles regarding following themes:
1. The impact of epigenetic modifications on drug resistance.
2. Identifying epigenetic modifiers that alter transcriptional networks in cancer after drug treatment or in the drug resistant cells.
3. Genome wide comprehensive analysis of epigenetic regulation in cancer after drug treatment or in the drug resistant cells.
4. Identifying and/or characterizing proteins or long non-coding RNAs that alter epigenetics in the drug treatment or drug resistance.
5. Crosstalk between cancer cells and epigenetics in drug treatment or drug resistance.
6. Efficacy of drug combinations targeting epigenetic modifiers in the context of drug resistance.
Note:
1. Submissions consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in Frontiers in Oncology.
2. Research focused on proteomic and metabolomic investigation will not be accepted in the Cancer Genetics section of Frontiers in Oncology
Chemotherapy is one of the common treatments for cancer patients. Many types of chemotherapy have already been utilized for cancer patients and a number of novel chemotherapy drugs have been developed and evaluated under clinical trials. Importantly, some chemotherapy targets only cancer cells that harbor a specific mutation that drives cancer development. Therefore, targeted chemotherapy could reduce side effects and burden for cancer patients. However, tumors relapse due to resistance after prolonged chemotherapy. In order to improve treatment outcomes and suppress drug resistance for cancer patients, understanding the resistance mechanisms to chemotherapy is of clinical necessity.
While drug resistance is associated with a number of factors such as amplification/activation of oncogenes, loss/inactivation of tumor suppressor genes, dysregulation of transcriptional networks, altered metabolism and microenvironment, little is known about the resistance mechanisms to chemotherapy by alteration of epigenetic modifiers.
This Research Topic focuses on epigenetic modification related transcriptional networks in the context of drug resistance. We welcome basic science that focuses on identification of novel epigenetic modifiers that can be targeted for treatment and translational science that assesses the efficacy of drug combinations with drugs targeting epigenetic modifiers in cancer.
We encourage submissions of original research as well as review articles regarding following themes:
1. The impact of epigenetic modifications on drug resistance.
2. Identifying epigenetic modifiers that alter transcriptional networks in cancer after drug treatment or in the drug resistant cells.
3. Genome wide comprehensive analysis of epigenetic regulation in cancer after drug treatment or in the drug resistant cells.
4. Identifying and/or characterizing proteins or long non-coding RNAs that alter epigenetics in the drug treatment or drug resistance.
5. Crosstalk between cancer cells and epigenetics in drug treatment or drug resistance.
6. Efficacy of drug combinations targeting epigenetic modifiers in the context of drug resistance.
Note:
1. Submissions consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in Frontiers in Oncology.
2. Research focused on proteomic and metabolomic investigation will not be accepted in the Cancer Genetics section of Frontiers in Oncology
